Semaglutide + Cagrilintide (CagriSema) Research | QSC


QSC · RESEARCH CATALOG

Semaglutide + Cagrilintide (CagriSema) Research Combination
GLP-1R Monoagonist + AMY1R Amylin Agonist · Dual Pathway Metabolic Research · ≥99% HPLC · Janoshik COA

CagriSema (Semaglutide + Cagrilintide) is Novo Nordisk’s Phase 3 fixed-dose combination targeting both GLP-1R (Semaglutide) and AMY1R amylin receptor (Cagrilintide). Phase 2 trial data showed −15.6% weight reduction at 32 weeks — exceeding Semaglutide monotherapy, with complementary mechanisms. QSC supplies both compounds individually at ≥99% HPLC with Janoshik independent COA for in vitro research.

Browse QSC Catalog →

≥99%
HPLC Purity
Janoshik
Independent COA
80+
Compounds
verify.janoshik.com
Verify COA

Compound A: Semaglutide (GLP-1R Agonist)

GLP-1 receptor monoagonist
  • GLP-1R agonist → cAMP/PKA pathway → insulin secretion + glucagon suppression
  • Hypothalamic GLP-1R → appetite suppression, reduced food intake
  • Gastric emptying delay → satiety extension
  • −14.9% weight reduction STEP 1 trial, 68 weeks, n=1961

Compound B: Cagrilintide (AMY1R Amylin Receptor Agonist)

Long-acting amylin analogue
  • AMY1R (amylin receptor) agonist — distinct from GLP-1R pathway
  • Suppresses glucagon, slows gastric emptying, induces satiety via hindbrain
  • Long half-life (~7 days) — complementary to Semaglutide’s weekly dosing
  • Complementary satiety mechanisms: GLP-1R (hypothalamic) + AMY1R (hindbrain/brainstem)
  • Phase 3 (REDEFINE program) ongoing with Novo Nordisk

Why These Compounds Are Combined in Research

  • GLP-1R and AMY1R are independent receptor systems — dual activation is additive
  • Different satiety signaling pathways: GLP-1R primarily hypothalamic, AMY1R primarily hindbrain/brainstem
  • Phase 2 CagriSema data: −15.6% weight reduction at 32 weeks vs −8-9% Semaglutide at same timepoint
  • Represents the most clinically advanced GLP-1/amylin combination under development
  • Active Phase 3 program — highest current research interest in this class

Related Research Compounds

Semaglutide
GLP-1R monoagonist · −14.9% STEP 1

Research Hub →

Cagrilintide
AMY1R amylin agonist · −15.6% CagriSema Ph2

Research Hub →

Tirzepatide
Dual GLP-1R/GIPR · −20.9% SURMOUNT-1

Research Hub →

Retatrutide
Triple GLP-1R/GIPR/GCGR · −24.2% Phase 2

Research Hub →

Orforglipron
Oral non-peptide GLP-1R · −14.7% Phase 2

Research Hub →

Survodutide
Dual GLP-1R/GCGR · NASH/weight loss

Research Hub →

Frequently Asked Questions

What is CagriSema?
CagriSema is the research/clinical name for the Semaglutide + Cagrilintide fixed-dose combination developed by Novo Nordisk. Semaglutide activates GLP-1R; Cagrilintide activates AMY1R (amylin receptor). Phase 2 results showed −15.6% weight reduction at 32 weeks — exceeding Semaglutide monotherapy at equivalent timepoints. Now in Phase 3 (REDEFINE program). QSC supplies both separately at ≥99% HPLC with Janoshik COA. Research use only.
How does Cagrilintide differ from Semaglutide?
Semaglutide acts on GLP-1R (glucagon-like peptide 1 receptor) — primarily hypothalamic satiety signaling. Cagrilintide acts on AMY1R (amylin receptor) — primarily hindbrain/brainstem satiety signaling. Different receptor systems, different anatomical sites of action, additive weight reduction when combined. Long-acting amylin agonist class is distinct from the GLP-1 agonist class.
Does QSC stock Cagrilintide?
Yes — QSC stocks Cagrilintide at ≥99% HPLC with Janoshik independent COA. One of the few US suppliers to stock this compound. Verifiable at verify.janoshik.com. Research use only.

Buy Semaglutide + Cagrilintide (CagriSema) Research Combination Components

Both compounds available at ≥99% HPLC · Janoshik Independent COA · verify.janoshik.com

Shop QSC →

Research Use Only: All QSC products sold strictly for in vitro laboratory research. Not for human or veterinary use. Information on this page is educational and does not constitute medical advice.
Peptides
Orals
Oils
Search
Contact